Jacqueline F. Price

Jacqueline F. Price

Auto-generated profile, based on publicly available information

Jacqueline F. Price

Usher Institute, University of Edinburgh, Edinburgh, UK

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2014 in Diabetes Care
Verified
Journal Article
Open access
PDF file
IFInsa Feinkohl
Insa Feinkohl
PAPhyu Phyu Aung
Phyu Phyu Aung
MKMarketa Keller
Marketa Keller
CRChristine M. Robertson
Christine M. Robertson
JMJoanne R. Morling
Joanne R. Morling
JPJackie F. Price
Jackie F. Price
OBJECTIVE People with type 2 diabetes are at increased risk of age-related cognitive decline and dementia. Hypoglycemia is a candidate risk factor, but the direction of association between episodes of severe hypoglycemia and cognitive decline in type 2 diabetes remains uncertain. RESEARCH DESIGN AND METHODS In the Edinburgh Type 2 Diabetes Study, cognitive function was assessed in 831 adults with type 2 diabetes (aged 60–75 years) at baseline and after 4 years. Scores on seven neuropsychological tests were combined into a standardized general ability factor g. Self-reported history of severe hypoglycemia at baseline (history of hypoglycemia) and at follow-up (incident hypoglycemia) was recorded. RESULTS A history of hypoglycemia was reported by 9.3% of subjects, and 10.2% reported incident hypoglycemia. Incident hypoglycemia was associated with poorer cognitive ability at baseline (age- and sex-adjusted odds ratio for lowest tertile of g 2.04 [95% CI 1.25–3.31], P = 0.004). Both history of hypoglycemia and incident hypoglycemia were also associated with greater cognitive decline during follow-up (mean follow-up g adjusted for age, sex, and baseline g −0.25 vs. 0.03 [P = 0.02] and −0.28 vs. 0.04 [P = 0.01], respectively), including after addition of vascular risk factors and cardiovascular and microvascular disease to the models (−0.23 vs. 0.03 [P = 0.04] and −0.21 vs. 0.05 [P = 0.03], respectively). CONCLUSIONS The relationship between cognitive impairment and hypoglycemia appeared complex, with severe hypoglycemia associated with both poorer initial cognitive ability and accelerated cognitive decline.

26 August 2010 in Diabetes
Verified
Journal Article
Open access
PDF file
JDJie Ding
Jie Ding
MSMark W.J. Strachan
Mark W.J. Strachan
RRRebecca Reynolds
Rebecca Reynolds
BFBrian M. Frier
Brian M. Frier
IDIan Deary
Ian Deary
JPJackie F. Price
Jackie F. Price
OBJECTIVE Cerebral microvascular disease associated with type 2 diabetes may exacerbate the effects of aging on cognitive function. A considerable homology exists between the retinal and cerebral microcirculations; a hypothesized association between diabetic retinopathy (DR) and cognitive decline was examined in older people with type 2 diabetes. RESEARCH DESIGN AND METHODS In the population-based Edinburgh Type 2 Diabetes Study, 1,046 men and women aged 60–75 years with type 2 diabetes underwent standard seven-field binocular digital retinal photography and a battery of seven cognitive function tests. A general cognitive ability score (g) was generated by principal components analysis. The Mill-Hill Vocabulary Scale was used to estimate premorbid cognitive ability. DR was graded using a modification of the Early Treatment of Diabetic Retinopathy Scale. RESULTS After age and sex adjustment, a significant relationship was observed with increasing severity of DR (none, mild, and moderate to severe) for most cognitive measures. Participants with moderate-to-severe retinopathy had the worst g and the worst performances on the individual tests. There was a significant interaction between sex and retinopathy for g. In male subjects, the associations of retinopathy with g (and with tests of verbal fluency, mental flexibility, and processing speed but not memory and nonverbal reasoning) persisted (P < 0.05) when further adjusted for vocabulary (to estimate lifetime cognitive decline), depression, sociodemographic characteristics, cardiovascular risk factors, and macrovascular disease. CONCLUSIONS DR was independently associated with estimated lifetime cognitive decline in older men with type 2 diabetes, supporting the hypothesis that cerebral microvascular disease may contribute to their observed accelerated age-related cognitive decline. A sex interaction with stronger findings in men requires further confirmation.

24 October 2011 in Diabetic Medicine
Verified
Journal Article
Closed access
PDF file
PAP. P. Aung
P. P. Aung
MSM. W. J. Strachan
M. W. J. Strachan
BFB. M. Frier
B. M. Frier
IBI. Butcher
I. Butcher
IDIan Deary
Ian Deary
OIon behalf of the Edinburgh Type 2 Diabetes Study Investigators
on behalf of the Edinburgh Type 2 Diabetes Study Investigators

1 October 2021 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Open access
PDF file
NZNatalie R. van Zuydam
Natalie R. van Zuydam
ASAlexander Stiby
Alexander Stiby
MAMoustafa Abdalla
Moustafa Abdalla
EAErin Austin
Erin Austin
EDEmma H. Dahlström
Emma H. Dahlström
Iftikhar KulloIftikhar Kullo
Iftikhar Kullo
Background: Peripheral artery disease (PAD) affects >200 million people worldwide and is associated with high mortality and morbidity. We sought to identify genomic variants associated with PAD overall and in the contexts of diabetes and smoking status. Methods: We identified genetic variants associated with PAD and then meta-analyzed with published summary statistics from the Million Veterans Program and UK Biobank to replicate their findings. Next, we ran stratified genome-wide association analysis in ever smokers, never smokers, individuals with diabetes, and individuals with no history of diabetes and corresponding interaction analyses, to identify variants that modify the risk of PAD by diabetic or smoking status. Results: We identified 5 genome-wide significant ( P association ≤5×10 −8 ) associations with PAD in 449 548 (N cases =12 086) individuals of European ancestry near LPA (lipoprotein [a]), CDKN2BAS1 (CDKN2B antisense RNA 1), SH2B3 (SH2B adaptor protein 3) - PTPN11 (protein tyrosine phosphatase non-receptor type 11), HDAC9 (histone deacetylase 9), and CHRNA3 (cholinergic receptor nicotinic alpha 3 subunit ) loci (which overlapped previously reported associations). Meta-analysis with variants previously associated with PAD showed that 18 of 19 published variants remained genome-wide significant. In individuals with diabetes, rs116405693 at the CCSER1 (coiled-coil serine rich protein 1 ) locus was associated with PAD (odds ratio [95% CI], 1.51 [1.32–1.74], P diabetes =2.5×10 −9 , P interactionwithdiabetes =5.3×10 −7 ). Furthermore, in smokers, rs12910984 at the CHRNA3 locus was associated with PAD (odds ratio [95% CI], 1.15 [1.11–1.19], P smokers =9.3×10 −10 , P interactionwithsmoking =3.9×10 −5 ). Conclusions: Our analyses confirm the published genetic associations with PAD and identify novel variants that may influence susceptibility to PAD in the context of diabetes or smoking status.

1 September 2008 in BMJ
Verified
Journal Article
Open access
PDF file
JPJackie F Price
Jackie F Price
MSMarlene C Stewart
Marlene C Stewart
IDIan J Deary
Ian J Deary
GMGordon D Murray
Gordon D Murray
PSPeter Sandercock
Peter Sandercock
OTOn Behalf Of The Aaa Trialists
On Behalf Of The Aaa Trialists
Objective To determine the effects of low dose aspirin on cognitive function in middle aged to elderly men and women at moderately increased cardiovascular risk. Design Randomised double blind placebo controlled trial. Setting Central Scotland. Participants 3350 men and women aged over 50 participating in the aspirin for asymptomatic atherosclerosis trial. Intervention Low dose aspirin (100 mg daily) or placebo for five years. Main outcome measures Tests of memory, executive function, non-verbal reasoning, mental flexibility, and information processing five years after randomisation, with scores used to create a summary cognitive score (general factor). Results At baseline, mean vocabulary scores (an indicator of previous cognitive ability) were similar in the aspirin (30.9, SD 4.7) and placebo (31.1, SD 4.7) groups. In the primary intention to treat analysis, there was no significant difference at follow-up between the groups in the proportion achieving over the median general factor cognitive score (32.7% and 34.8% respectively, odds ratio 0.91, 95% confidence interval 0.79 to 1.05, P=0.20) or in mean scores on the individual cognitive tests. There were also no significant differences in change in cognitive ability over the five years in a subset of 504 who underwent detailed cognitive testing at baseline. Conclusion Low dose aspirin does not affect cognitive function in middle aged to elderly people at increased cardiovascular risk. Trial registration ISRCTN 66587262.

30 January 2021 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
TATarunveer Singh Ahluwalia
Tarunveer Singh Ahluwalia
BPBram P Prins
Bram P Prins
MAMohammadreza Abdollahi
Mohammadreza Abdollahi
NANicola J Armstrong
Nicola J Armstrong
SAStella Aslibekyan
Stella Aslibekyan
BABehrooz Z. Alizadeh
Behrooz Z. Alizadeh
Interleukin 6 (IL-6) is a multifunctional cytokine with both pro- and anti-inflammatory properties with a heritability estimate of up to 61%. The circulating levels of IL-6 in blood have been associated with an increased risk of complex disease pathogenesis. We conducted a two-staged, discovery and replication meta genome-wide association study (GWAS) of circulating serum IL-6 levels comprising up to 67 428 (ndiscovery = 52 654 and nreplication = 14 774) individuals of European ancestry. The inverse variance fixed effects based discovery meta-analysis, followed by replication led to the identification of two independent loci, IL1F10/IL1RN rs6734238 on chromosome (Chr) 2q14, (Pcombined = 1.8 × 10−11), HLA-DRB1/DRB5 rs660895 on Chr6p21 (Pcombined = 1.5 × 10−10) in the combined meta-analyses of all samples. We also replicated the IL6R rs4537545 locus on Chr1q21 (Pcombined = 1.2 × 10−122). Our study identifies novel loci for circulating IL-6 levels uncovering new immunological and inflammatory pathways that may influence IL-6 pathobiology.